DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...